vs
Amneal Pharmaceuticals, Inc.（AMRX）とMativ Holdings, Inc.（MATV）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amneal Pharmaceuticals, Inc.の直近四半期売上が大きい（$814.3M vs $463.1M、Mativ Holdings, Inc.の約1.8倍）。Mativ Holdings, Inc.の純利益率が高く（21.8% vs 4.3%、差は17.5%）。Amneal Pharmaceuticals, Inc.の前年同期比売上増加率が高い（11.5% vs 1.0%）。Amneal Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$108.5M vs $8.0M）。過去8四半期でAmneal Pharmaceuticals, Inc.の売上複合成長率が高い（11.1% vs -3.8%）
アムニールファーマシューティカルズは米国の上場製薬企業で、後発医薬品と専門医薬品の開発・製造・流通を事業の柱としています。本社はニュージャージー州ブリッジウォーターに位置し、米国最大級の後発医薬品メーカーの1つです。
Mativ Holdings, Inc.は世界的な特殊材料メーカーで、高性能先端ポリマー、不織布、ろ過ソリューション、機能性コーティング材料を製造しています。医療、産業、消費財、航空宇宙、エネルギー分野に顧客を持ち、北米、欧州、アジア太平洋地域で事業を展開しています。
AMRX vs MATV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $814.3M | $463.1M |
| 純利益 | $35.1M | $100.8M |
| 粗利率 | 36.5% | 18.8% |
| 営業利益率 | 13.8% | 2.2% |
| 純利益率 | 4.3% | 21.8% |
| 売上前年比 | 11.5% | 1.0% |
| 純利益前年比 | 212.9% | 6620.0% |
| EPS（希薄化後） | $0.10 | $1.87 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $814.3M | $463.1M | ||
| Q3 25 | $784.5M | $513.7M | ||
| Q2 25 | $724.5M | $525.4M | ||
| Q1 25 | $695.4M | $484.8M | ||
| Q4 24 | $730.5M | $458.6M | ||
| Q3 24 | $702.5M | $498.5M | ||
| Q2 24 | $701.8M | $523.8M | ||
| Q1 24 | $659.2M | $500.2M |
| Q4 25 | $35.1M | $100.8M | ||
| Q3 25 | $2.4M | $-3.2M | ||
| Q2 25 | $22.4M | $-9.5M | ||
| Q1 25 | $12.2M | $-425.5M | ||
| Q4 24 | $-31.1M | $1.5M | ||
| Q3 24 | $-156.0K | $-20.8M | ||
| Q2 24 | $6.0M | $-1.4M | ||
| Q1 24 | $-91.6M | $-28.0M |
| Q4 25 | 36.5% | 18.8% | ||
| Q3 25 | 34.9% | 19.3% | ||
| Q2 25 | 39.5% | 19.7% | ||
| Q1 25 | 36.8% | 15.0% | ||
| Q4 24 | 36.0% | 16.9% | ||
| Q3 24 | 38.4% | 18.8% | ||
| Q2 24 | 35.6% | 20.8% | ||
| Q1 24 | 36.1% | 16.8% |
| Q4 25 | 13.8% | 2.2% | ||
| Q3 25 | 9.0% | 3.1% | ||
| Q2 25 | 15.4% | 3.8% | ||
| Q1 25 | 14.4% | -88.8% | ||
| Q4 24 | 10.4% | 0.6% | ||
| Q3 24 | 12.6% | 1.4% | ||
| Q2 24 | 13.6% | 2.0% | ||
| Q1 24 | -1.6% | -2.8% |
| Q4 25 | 4.3% | 21.8% | ||
| Q3 25 | 0.3% | -0.6% | ||
| Q2 25 | 3.1% | -1.8% | ||
| Q1 25 | 1.8% | -87.8% | ||
| Q4 24 | -4.3% | 0.3% | ||
| Q3 24 | -0.0% | -4.2% | ||
| Q2 24 | 0.9% | -0.3% | ||
| Q1 24 | -13.9% | -5.6% |
| Q4 25 | $0.10 | $1.87 | ||
| Q3 25 | $0.01 | $-0.06 | ||
| Q2 25 | $0.07 | $-0.18 | ||
| Q1 25 | $0.04 | $-7.82 | ||
| Q4 24 | $-0.10 | $0.03 | ||
| Q3 24 | $0.00 | $-0.38 | ||
| Q2 24 | $0.02 | $-0.03 | ||
| Q1 24 | $-0.30 | $-0.52 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.0M | $84.2M |
| 総負債低いほど良い | $2.6B | $1.0B |
| 株主資本純資産 | $-70.8M | $498.7M |
| 総資産 | $3.7B | $2.1B |
| 負債/資本比率低いほどレバレッジが低い | — | 2.07× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.0M | $84.2M | ||
| Q3 25 | $201.2M | $97.1M | ||
| Q2 25 | $71.5M | $95.6M | ||
| Q1 25 | $59.2M | $84.0M | ||
| Q4 24 | $110.6M | $94.3M | ||
| Q3 24 | $74.0M | $162.2M | ||
| Q2 24 | $43.8M | $133.4M | ||
| Q1 24 | $46.5M | $128.9M |
| Q4 25 | $2.6B | $1.0B | ||
| Q3 25 | $2.6B | $1.0B | ||
| Q2 25 | $2.2B | $1.1B | ||
| Q1 25 | $2.2B | $1.1B | ||
| Q4 24 | $2.4B | $1.1B | ||
| Q3 24 | $2.4B | $1.2B | ||
| Q2 24 | $2.4B | $1.2B | ||
| Q1 24 | $2.4B | $1.2B |
| Q4 25 | $-70.8M | $498.7M | ||
| Q3 25 | $-109.5M | $397.4M | ||
| Q2 25 | $-112.1M | $416.6M | ||
| Q1 25 | $-131.7M | $428.2M | ||
| Q4 24 | $-109.3M | $858.5M | ||
| Q3 24 | $-93.4M | $882.3M | ||
| Q2 24 | $-57.5M | $898.0M | ||
| Q1 24 | $-63.7M | $906.9M |
| Q4 25 | $3.7B | $2.1B | ||
| Q3 25 | $3.6B | $2.0B | ||
| Q2 25 | $3.4B | $2.1B | ||
| Q1 25 | $3.4B | $2.1B | ||
| Q4 24 | $3.5B | $2.4B | ||
| Q3 24 | $3.5B | $2.6B | ||
| Q2 24 | $3.5B | $2.6B | ||
| Q1 24 | $3.5B | $2.7B |
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.63× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 1.30× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $130.3M | $19.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $108.5M | $8.0M |
| FCFマージンFCF / 売上 | 13.3% | 1.7% |
| 設備投資強度設備投資 / 売上 | 2.7% | 2.4% |
| キャッシュ転換率営業CF / 純利益 | 3.72× | 0.19× |
| 直近12ヶ月FCF直近4四半期 | $269.9M | $93.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $130.3M | $19.3M | ||
| Q3 25 | $118.5M | $72.8M | ||
| Q2 25 | $83.8M | $57.6M | ||
| Q1 25 | $7.4M | $-15.9M | ||
| Q4 24 | $118.1M | $24.1M | ||
| Q3 24 | $141.8M | $37.6M | ||
| Q2 24 | $39.7M | $46.1M | ||
| Q1 24 | $-4.4M | $-13.0M |
| Q4 25 | $108.5M | $8.0M | ||
| Q3 25 | $106.2M | $66.7M | ||
| Q2 25 | $61.0M | $48.9M | ||
| Q1 25 | $-5.8M | $-29.8M | ||
| Q4 24 | $102.9M | $2.0M | ||
| Q3 24 | $124.8M | $25.5M | ||
| Q2 24 | $29.0M | $37.4M | ||
| Q1 24 | $-13.6M | $-25.1M |
| Q4 25 | 13.3% | 1.7% | ||
| Q3 25 | 13.5% | 13.0% | ||
| Q2 25 | 8.4% | 9.3% | ||
| Q1 25 | -0.8% | -6.1% | ||
| Q4 24 | 14.1% | 0.4% | ||
| Q3 24 | 17.8% | 5.1% | ||
| Q2 24 | 4.1% | 7.1% | ||
| Q1 24 | -2.1% | -5.0% |
| Q4 25 | 2.7% | 2.4% | ||
| Q3 25 | 1.6% | 1.2% | ||
| Q2 25 | 3.2% | 1.7% | ||
| Q1 25 | 1.9% | 2.9% | ||
| Q4 24 | 2.1% | 4.8% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 1.5% | 1.7% | ||
| Q1 24 | 1.4% | 2.4% |
| Q4 25 | 3.72× | 0.19× | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | 16.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
